Fabian Lohaus1, Annett Linge1, Inge Tinhofer2, Volker Budach2, Eleni Gkika3, Martin Stuschke3, Panagiotis Balermpas4, Claus Rödel5, Melanie Avlar6, Anca-Ligia Grosu7, Amir Abdollahi8, Jürgen Debus9, Christine Bayer10, Claus Belka11, Steffi Pigorsch12, Stephanie E Combs12, David Mönnich13, Daniel Zips13, Cläre von Neubeck14, Gustavo B Baretton15, Steffen Löck16, Howard D Thames17, Mechthild Krause18, Michael Baumann19. 1. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Dresden, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 2. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany. 3. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Essen, Germany; Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany. 4. Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany. 5. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Frankfurt, Germany; Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany. 6. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Freiburg, Germany; Department of Radiation Oncology, Clinical Study Section, University of Freiburg, Germany. 7. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Freiburg, Germany; Department of Radiation Oncology, University of Freiburg, Germany. 8. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Heidelberg, Germany; Department of Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Translational Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany. 9. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Heidelberg, Germany; Department of Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany; Clinical Cooperation Unit Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany. 10. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Munich, Germany. 11. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Munich, Germany; Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany. 12. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Munich, Germany; Department of Radiation Oncology, Technische Universität München, Germany. 13. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Tübingen, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls Universität Tübingen, Germany. 14. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 15. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Dresden, Germany; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Tumor- and Normal Tissue Bank, Universitäts KrebsCentrum (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 16. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 17. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. 18. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Dresden, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Institute of Radiooncology, Helmholtz-Zentrum Dresden - Rossendorf, Germany. 19. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites: Dresden, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Institute of Radiooncology, Helmholtz-Zentrum Dresden - Rossendorf, Germany. Electronic address: Michael.Baumann@uniklinikum-dresden.de.
Abstract
OBJECTIVE: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. MATERIALS AND METHODS: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. RESULTS: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases. CONCLUSIONS: HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.
OBJECTIVE: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. MATERIALS AND METHODS: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. RESULTS: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases. CONCLUSIONS:HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.
Authors: Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld Journal: Nat Rev Cancer Date: 2016-03-18 Impact factor: 60.716
Authors: Pirus Ghadjar; Christoph Pöttgen; Daniela Joos; Stefanie Hayoz; Michael Baumann; Stephan Bodis; Wilfried Budach; Gabriela Studer; Carmen Stromberger; Frank Zimmermann; David Kaul; Ludwig Plasswilm; Heidi Olze; Jacques Bernier; Peter Wust; Daniel M Aebersold; Volker Budach Journal: Strahlenther Onkol Date: 2016-06-20 Impact factor: 3.621
Authors: Eva-Leonne Göttgens; Christian Ostheimer; Paul N Span; Jan Bussink; Ester M Hammond Journal: Br J Radiol Date: 2018-03-14 Impact factor: 3.039
Authors: Elke Beyreuther; Michael Baumann; Wolfgang Enghardt; Stephan Helmbrecht; Leonhard Karsch; Mechthild Krause; Jörg Pawelke; Lena Schreiner; Michael Schürer; Cläre von Neubeck; Armin Lühr Journal: Int J Part Ther Date: 2018-09-21